Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anidulafungin: a novel echinocandin.

Jose A Vazquez1, Jack D Sobel

  • 1Division of Infectious Diseases, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, Michigan 48202, USA. jvazque1@hfhs.org

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 17, 2006
PubMed
Summary

Anidulafungin, a novel echinocandin antifungal, shows potent activity against serious fungal infections, including drug-resistant strains. Clinical trials demonstrate its effectiveness and favorable safety profile, positioning it as a valuable treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame Topic

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.

Mycoses·2026
Same author

Phenotypic and genotypic analysis of <i>Candida albicans</i> vaginal isolates reveals that <i>ECE1</i> expression underpins pathogenicity.

Infection and immunity·2026
Same author

Light-Enhanced Electrochemical Performance of Fish Waste-Derived Carbon-TiO<sub>2</sub> Composites for Sustainable Energy Storage Systems.

Nanomaterials (Basel, Switzerland)·2026
Same author

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis.

Infection and drug resistance·2026
Same author

Sexual transmission of vaginal pathogens and male partner treatment: is it time to consider vulvovaginal candidiasis?

Sexually transmitted infections·2026
Same author

State-of-the-Art Review: Managing Vulvovaginal Candidiasis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Traditional antifungals like amphotericin B and azoles have limitations.
  • Serious fungal infections require effective and safe treatment options.

Purpose of the Study:

  • To evaluate the efficacy and safety of anidulafungin, a novel echinocandin.
  • To compare anidulafungin with fluconazole for treating candidemia and invasive candidiasis.

Main Methods:

  • In vitro studies assessing activity against Aspergillus and Candida species.
  • Clinical trials evaluating anidulafungin for esophageal candidiasis and candidemia.
  • Drug interaction studies with concomitant medications.

Main Results:

Related Experiment Videos

  • Anidulafungin exhibits potent in vitro activity, including against fluconazole-resistant strains.
  • Clinical trials show efficacy in esophageal candidiasis and superiority over fluconazole in candidemia.
  • No significant drug-drug interactions or adverse events observed with concomitant use.

    • Conclusions:

    • Anidulafungin demonstrates potent antifungal activity and a favorable safety profile.
    • It is effective for esophageal candidiasis and superior to fluconazole for candidemia.
    • Anidulafungin is a promising new agent for managing difficult fungal infections.